Meraj Siddiqui

Dr. Meraj Siddiqui

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in Clinical and Experimental Pediatrics
Verified
Journal Article
Open access
PDF file
MSMeraj Siddiqui
Meraj Siddiqui
AGAyşe Gültekingil
Ayşe Gültekingil
OBOğuz Bakırcı
Oğuz Bakırcı
NUNihal Uslu
Nihal Uslu
EBEsra Baskın
Esra Baskın
Background: As the coronavirus disease 2019 (COVID-19) outbreak continues to evolve, it is crucially important for pediatricians to be aware of the differences in demographic and clinical features between COVID-19 and influenza A and B infections.Purpose: This study analyzed and compared the clinical features and laboratory findings of COVID-19 and influenza A and B infections in children.Methods: This retrospective study evaluated the medical data of 206 pediatric COVID-19 and 411 pediatric seasonal influenza A or B patients.Results: COVID-19 patients were older than seasonal influenza patients (median [interquartile range], 7.75 [2–14] years vs. 4 [2–6] years). The frequency of fever and cough in COVID-19 patients was lower than that of seasonal influenza patients (80.6% vs. 94.4%, P<0.001 and 22.8 % vs. 71.5%, P<0.001, respectively). Ageusia (4.9%) and anosmia (3.4%) were present in only COVID-19 patients. Leukopenia, lymphopenia, and thrombocytopenia were encountered more frequently in influenza patients than in COVID-19 patients (22.1% vs. 8.5%, P=0.029; 17.6% vs. 5.6%, P=0.013; and 13.2% vs. 5.6%, P= 0.048, respectively). Both groups showed significantly elevated monocyte levels in the complete blood count (70.4% vs. 69.9%, P=0.511). Major chest x-ray findings in COVID-19 patients included mild diffuse ground-glass opacity and right lower lobe infiltrates. There were no statistically significant intergroup differences in hospitalization or mortality rates; however, the intensive care unit admission rate was higher among COVID-19 patients (2.4% vs. 0.5%, P=0.045).Conclusion: In this study, pediatric COVID-19 patients showed a wide range of clinical presentations ranging from asymptomatic/mild to severe illness. We found no intergroup differences in hospitalization rates, oxygen requirements, or hospital length of stay; however, the intensive care unit admission rate was higher among COVID-19 patients.

7 June 2023 in Pediatric Transplantation
Verified
Journal Article
Closed access
EBEsra Baskin
Esra Baskin
MSMeraj Siddiqui
Meraj Siddiqui
KGKaan Gülleroğlu
Kaan Gülleroğlu
BÖBinnaz Handan Özdemir
Binnaz Handan Özdemir
AYAysun Çaltık Yılmaz
Aysun Çaltık Yılmaz
MHMehmet Haberal
Mehmet Haberal

1 May 2022 in Experimental and Clinical Transplantation
Verified
Journal Article
Closed access
MSMeraj Siddiqui
Meraj Siddiqui
EBEsra Baskin
Esra Baskin
KGKaan Savaş Gülleroğlu
Kaan Savaş Gülleroğlu
AYAysun Çaltik Yilmaz
Aysun Çaltik Yilmaz
GMGökhan Moray
Gökhan Moray
MHMehmet Haberal
Mehmet Haberal
Delayed graft function is a common adverse outcome after renal transplant. Attempts for early prediction and prevention of delayed graft function are often challenging and misleading. Herein, we investigated for the first time the correlation between delayed graft function and preoperative noninvasive hematologic parameters to predict the possible adverse outcomes for renal transplant in pediatric patients. In this study, preoperative hematologic parameters of 51 pediatric renal transplant recipients followed between 2015 and 2021 were analyzed retrospectively. The selected 16 renal transplant patients with delayed graft function and 35 patients without delayed graft function had no concomitant comorbidities. The cutoff values for platelet-to-lymphocyte ratio of <5 and neutrophilto- lymphocyte ratio of <175 were considered low. We retrospectively evaluated a total of 51 (male/female, 33/18) pediatric kidney transplant recipients with a median age of 12 (interquartile range, 8-18) years. Median level of circulating lymphocytes was significantly higher in patients with delayed graft function compared with patients without delayed graft function (2 vs 1, P = .040). The preoperative low values for platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio were more prevalent in recipients who developed delayed graft function versus those who did not develop delayed graft function (68.8% vs 31.4% [P = .014] and 68.8% vs 34.3% [P = .023], respectively). Pretransplant low platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte were associated with increased number of delayed graft dysfunction. These novels and noninvasive inflammatory biomarkers may contribute to an early prediction of delayed graft function in pediatric kidney transplant recipients.

1 May 2022 in Experimental and Clinical Transplantation
Verified
Journal Article
Closed access
MSMeraj Siddiqui
Meraj Siddiqui
EBEsra Baskin
Esra Baskin
FKFeza Yarbug Karakayali
Feza Yarbug Karakayali
AGAtilla Gemici
Atilla Gemici
KGKaan Gulleroglu
Kaan Gulleroglu
MHMehmet Haberal
Mehmet Haberal
Late antibody-mediated rejection triggered by donor-specific antibodies is a leading cause of kidney allograft failure. Effective treatment options for late antibody-mediated rejection are limited in renal transplant recipients. Here, we report 2 pediatric cases of severe late antibody-mediated rejection resistant to conventional immunosuppressive therapy who were successfully treated with eculizumab. Two patients who fulfilled the late antibody-mediated rejection diagnostic criteria (positive donor-specific antibodies, elevated mean fluorescence index, acute and/or chronic morphological lesions in the microvasculature, and abnormal kidney function test) were included in this study. Both patients were previously unsensitized with negative panel-reactive antibody. Case 1 was a 12-year-old male patient with kidney failure secondary to vesicoureteral reflux who underwent related-living donor kidney transplantation 2 years ago. Eleven months later, he was diagnosed with late antibody-mediated rejection. Despite an aggressive conventional immunosuppressive regimen, signs of rejection persisted. After the patient was treated with 2 doses of eculizumab, his mean fluorescence index dropped and serum creatinine decreased from 3.8 to 1.5 mg/dL. Case 2 was an unsensitized 16-year-old male patient with kidney failure secondary posterior urethral valve who underwent related-living donor kidney transplantation 4 years ago. Two years later, he was diagnosed with late antibody-mediated rejection. Despite an aggressive conventional immunosuppressive regimen, signs of rejection persisted. After treatment with 2 doses of eculizumab, his mean fluorescence index dropped and serum creatinine decreased from 2.1 to 1.01 mg/dL. In both patients, eculizumab therapy effectively reduced the markers of late antibody-mediated rejection and improved the kidney function.

11 February 2026 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
UDUtku Dönger
Utku Dönger
MSMeraj Siddiqui
Meraj Siddiqui
AYAysun Çaltık Yılmaz
Aysun Çaltık Yılmaz
CICaner İnCekaş
Caner İnCekaş
EBEsra Baskın
Esra Baskın
Background: The urinary calcium-to-citrate (Ca/Cit) ratio has emerged as a useful indicator of lithogenic risk in older children; however, no reference data exist for infants and toddlers. This study aimed to evaluate whether the spot Ca/Cit ratio can distinguish stone-forming from non–stone-forming children under 24 months of age and to assess its diagnostic performance compared with conventional urinary markers. Methods: This retrospective single-center study included 181 children aged 1–24 months who underwent metabolic evaluation and ultrasonography at their first presentation to a tertiary pediatric nephrology clinic between 2012 and 2024. Based on urinary calcium excretion and ultrasonographic findings, participants were categorized as normocalciuric stone-free controls ( n = 57), hypercalciuric stone-formers ( n = 29), or non-hypercalciuric stone-formers ( n = 95). Spot urine calcium, citrate, and related biochemical ratios were analyzed. The diagnostic accuracy of the Ca/Cit ratio for predicting stones was assessed using receiver operating characteristic (ROC) analysis. Results: The Ca/Cit ratio differed significantly across groups, with the highest levels observed in hypercalciuric stone-formers (0.46 mg/mg) compared with controls (0.17 mg/mg; p < 0.001) and non-hypercalciuric stone-formers (0.31 mg/mg; p < 0.001). A Ca/Cit threshold > 0.23 mg/mg (≈ 1.10 mmol/mmol) demonstrated moderate diagnostic ability for stone detection (AUC 0.695; 95% CI 0.613–0.785), yielding 66.1% sensitivity and 63.2% specificity. Age showed no meaningful correlation with Ca/Cit values. Normocalciuric stone-free children provided an age-appropriate reference distribution for Ca/Cit ratios. Conclusions: In infants and toddlers evaluated for suspected urinary stone disease, the Ca/Cit ratio offers moderate discriminatory power and may serve as a practical adjunctive marker of stone risk. A ratio > 0.23 mg/mg (≈ 1.10 mmol/mmol) appears to indicate increased lithogenic potential. Larger prospective studies are needed to validate reference intervals and refine clinically applicable cut-off values for this young age group.

1 May 2022 in Experimental and Clinical Transplantation
Verified
Journal Article
Closed access
MSMeraj Siddiqui
Meraj Siddiqui
OBOğuz Bakirci
Oğuz Bakirci
UDUtku Dönger
Utku Dönger
KWKhaled Warasnhe
Khaled Warasnhe
FÖFigen Özçay
Figen Özçay
MHMehmet Haberal
Mehmet Haberal
Objectives: Several studies suggest that chronic immunosuppression in pediatric liver transplant patients may affect the severity and mortality rates of SARS-CoV-2 infection. Materials and Methods: We assessed a total of 118 pediatric liver transplant recipients for SARS-CoV-2 infection, aged 1 to 18 years, followed between March 2019 and January 2022. We compared the clinical characteristics and outcomes of SARS-CoV-2 infection in pediatric liver transplant patients to 187 non-liver transplant pediatric patients with SARS-CoV-2 infection who had been diagnosed at our institution between March 15, 2020, and December 31, 2020. Demographic data, clinical features, and laboratory findings from the patients were retrospectively collected from hospital reports and telephone inquiries. Results: A total of 20 liver transplant patients with SARS-CoV-2 infection were identified. Median age of liver transplant recipients with SARS-CoV-2 infection was higher than non-liver transplant pediatric patients with SARS-CoV-2 (14.8 [range, 7-16] vs 6.8 [range, 2-14] years; P = .016). There were no significant differences in mild and moderate disease courses of SARS-CoV-2 infection between liver transplant recipients and non-liver transplant pediatric patients (18 [90.0%] vs 133 [71.1%] patients [P = .188] and 2 [10%] vs 49 [26.2%] patients [P = .118], respectively). Fever was less frequently observed in liver transplant patients with SARS-CoV-2 infection compared with non-liver transplant patients (55.0% vs 80.2%; P = .015). We found no intergroup differences in sex (P = .342), hospitalization rate (P = .161), and overall clinical presentation. Conclusions: Despite the immunosuppression regimens, liver transplant patients in our series survived SARS-CoV-2 infection without serious sequelae and without graft rejection. Overall, liver transplant and non-liver transplant pediatric patients with SARS-CoV-2 infection experienced a mild disease course.